Equity Profile
Pre-Earnings Brief
GSK plc is a global healthcare company focused on pharmaceuticals, vaccines, and consumer health products. With a market cap of $108 billion, GSK plays a significant role in the healthcare sector, especially in developing treatments and vaccines that address major health challenges.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue reflects the company's ability to generate sales, which is crucial for sustaining operations and growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-32.34%
Avg Stock Reaction
-0.73%
In the last quarter, GSK reported an EPS of $0.45, which was significantly below the expected $0.88, leading to a negative surprise of over 48%. The stock reacted positively the following day, gaining 2.79%.
Management Promises & Guidance
Analysts expect GSK to report an EPS of $1.16 and revenue of $7.6 billion for Q1-2011. The market is watching closely for any signs of recovery after a disappointing last quarter.
Bull Case
If GSK can meet or exceed EPS and revenue expectations, it may signal a turnaround in performance, boosting investor confidence and potentially leading to a stock price increase.
Bear Case
Conversely, if GSK misses expectations again, it could raise concerns about the company's growth prospects and lead to a further decline in stock price.
Earnings Per Share (EPS)
$1.16EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$7.6BRevenue reflects the company's ability to generate sales, which is crucial for sustaining operations and growth.
Expectations
The print will turn on these two things.
Q1
Will GSK's EPS meet or exceed the consensus estimate of $1.16?
This figure is crucial for assessing the company's profitability and could significantly impact investor sentiment.
Q2
What factors contributed to the revenue forecast of $7.6 billion?
Understanding the drivers behind revenue expectations will help investors gauge the company's growth potential and market position.
Edge
Why consensus could be wrong
The consensus may underestimate GSK's potential for recovery, as recent developments in its pipeline could lead to better-than-expected results.
Supporting Evidence
GSK's historical performance shows a tendency to surprise positively after a miss, which could indicate a rebound.
The options market is pricing a larger move than historical averages, suggesting that traders are anticipating significant news.
The company's recent investments in R&D may not be fully reflected in current estimates, potentially leading to upside surprises.
Key Risk
If GSK's revenue comes in significantly above $7.6 billion, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a significant earnings miss, and the market is eager to see if GSK can rebound.
Bull Confirmed If
Achieving an EPS of $1.16 or higher would confirm the bull case and indicate a strong recovery.
Bear Confirmed If
An EPS below $1.15 would confirm the bear case, raising concerns about ongoing challenges.
Pre-Earnings Positioning
Implied Move
±4.4%
Historical Avg
±2.0%
The options market is pricing in a significant move of approximately 4.4%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±12.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
29.6%
Edge
Smart-money positioning from the most recent 13F filings.
Institutional
19.80%
of float
Insider
0.06%
of float
Holders
1,142
institutions
Top Holders· as of Dec 2025
Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%
FMR, LLC
67,469,409 sh · $3.7B
3.32%
2.0%
Fisher Asset Management, LLC
33,195,985 sh · $1.8B
1.64%
3.0%
Primecap Management Company
25,130,160 sh · $1.4B
1.24%
-2.5%
JTC Employer Solutions Trustee Ltd.
14,428,009 sh · $785.5M
0.71%
-1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If GSK beats expectations, history suggests the stock could rise, potentially reflecting improved investor confidence.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 0.83% in such cases.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Southern Copper Corporation